MaxCyte, Inc. cash flow to debt ratio of -191.77% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

MaxCyte, Inc.'s free cash flow has decreased 23.64% from $-29.26M last year to $-36.18M, signaling decreasing performance

MaxCyte, Inc.'s debt to equity ratio is 0.10, which means that the company's assets are healthy financed, signaling financial stability.

MaxCyte, Inc.'s debt has increased relative to shareholder equity from 0.09 last year to 0.10 today, signaling weakened financials

MaxCyte, Inc. has a net cash position, so leverage is healthy.

MaxCyte, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

MaxCyte, Inc.'s profit margin has decreased (13.99%) in the last year from -106.29% to -121.16%, signaling decreasing performance

MaxCyte, Inc.'s short-term assets of $118.37M exceed its short-term liabilities of $14.27M

MaxCyte, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

MaxCyte, Inc.'s return on equity of -22.03%, is lower than 15.00%, indicating bad performance

MaxCyte, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

MaxCyte, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

MaxCyte, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

MaxCyte, Inc. has negative free cash flow, indicating cash burn

MaxCyte, Inc.'s yearly earnings has decreased 8.71% since last year from $-41.05M to $-44.63M, signaling decreasing performance

MaxCyte, Inc.'s yearly revenue has decreased 14.50% since last year from $38.63M to $33.03M, signaling decreasing performance

ROIC -20.82% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

MaxCyte, Inc.'s 3-year revenue CAGR of -9.30% is negative, indicating declining revenue over the past 3 years

MaxCyte, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

MaxCyte, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

MaxCyte, Inc. has insufficient data to evaluate this check.

MaxCyte, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

MaxCyte, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

MaxCyte, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

MaxCyte, Inc. has insufficient data to evaluate this check.

MaxCyte, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

MaxCyte, Inc. has a price-to-book ratio of 0.77x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

MaxCyte, Inc. has a price-to-sales ratio of 4.01x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue